Efficacy and safety of switching to iGlarLixi from premixed insulins in people with type 2 diabetes: The Soli‐ SWITCH study

Documenti analoghi

• Efficacy and safety of iGlarLixi versus IDegAsp by baseline β‐cell function in Chinese people with type 2 diabetes: Exploratory analyses of the Soli‐D study
  di: Weijun Gu, et al.
  Pubblicazione: (2025)
• Real‐life effectiveness of iGlarLixi (insulin glargine 100 U/mL and lixisenatide) in people with type 2 diabetes according to prior insulin use
  di: Jochen Seufert, et al.
  Pubblicazione: (2024)
• The efficacy and safety of iGlarLixi versus IDegAsp in Chinese people with type 2 diabetes suboptimally controlled with oral antidiabetic drugs: The Soli‐D randomized controlled trial
  di: Ming Liu, et al.
  Pubblicazione: (2024)
• Time‐in‐range derived from self‐measured blood glucose in people with type 2 diabetes advancing to iGlarLixi : A participant‐level pooled analysis of three phase 3 LixiLan randomized controlled trials
  di: Martin Haluzík, et al.
  Pubblicazione: (2024)
• Effects of age and disease duration on the efficacy and safety of iGlarLixi in Asian people with type 2 diabetes: A post hoc analysis of the LixiLan‐O‐AP and LixiLan‐L‐CN trials
  di: Wenying Yang, et al.
  Pubblicazione: (2024)